Knoepfler Lab

Weekly regenerative & stem cell reads: much more FDA flexibility on rare diseases, elephant iPS cells pub (they're still intent on mammoth de-extinction effort?), heritable human CRISPR and NANOG, RTT rarely used, digit regeneration https://ipscell.com/2026/06/weekly-reads-more-fda-flexibility-on-rare-diseases-elephant-ips-cells-heritable-human-crispr-rtt-rarely-used-digit-regeneration

ipscell.com

Perspectives on FDA's Megha Kaushal talk at ASGCT 2026: PFDD, patient voices, decision-making https://ipscell.com/2026/05/fdas-megha-kaushal-talk-pfdd-patient-voices-decision-making How will PFDD evolve in a chaotic, politic FDA?

FDA's Megha Kaushal talk: PFDD, patient voices, decision-making - The Niche Professor's perspectives on ASCGT talk by FDA on Integrating Patient Voices into Regulatory Decision-Making on CGT and PFDD.